

Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Growth 2023-2029

<https://marketpublishers.com/r/G7FC0D28E5ABEN.html>

Date: February 2023

Pages: 71

Price: US\$ 3,660.00 (Single User License)

ID: G7FC0D28E5ABEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.

LPI (LP Information)' newest research report, the "Idiopathic Pulmonary Fibrosis (IPF) Drug Industry Forecast" looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis (IPF) Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis (IPF) Drug sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis (IPF) Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Idiopathic Pulmonary Fibrosis (IPF) Drug industry.

This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis (IPF) Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis (IPF) Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Idiopathic Pulmonary Fibrosis (IPF) Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis (IPF) Drug and breaks

down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis (IPF) Drug.

The global Idiopathic Pulmonary Fibrosis (IPF) Drug market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Idiopathic Pulmonary Fibrosis (IPF) Drug is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Idiopathic Pulmonary Fibrosis (IPF) Drug is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Idiopathic Pulmonary Fibrosis (IPF) Drug is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Idiopathic Pulmonary Fibrosis (IPF) Drug players cover American Lung Association, Roche, Genentech and Fierce Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis (IPF) Drug market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Nintedanib

Pirfenidone

Segmentation by application

Hospital

Clinics

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

American Lung Association

Roche

Genentech

Fierce Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Idiopathic Pulmonary Fibrosis (IPF) Drug market?

What factors are driving Idiopathic Pulmonary Fibrosis (IPF) Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Idiopathic Pulmonary Fibrosis (IPF) Drug market opportunities vary by end market size?

How does Idiopathic Pulmonary Fibrosis (IPF) Drug break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Idiopathic Pulmonary Fibrosis (IPF) Drug by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Idiopathic Pulmonary Fibrosis (IPF) Drug by Country/Region, 2018, 2022 & 2029

2.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Segment by Type

- 2.2.1 Nintedanib
- 2.2.2 Pirfenidone

2.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type

- 2.3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)
- 2.3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Type (2018-2023)

2.4 Idiopathic Pulmonary Fibrosis (IPF) Drug Segment by Application

- 2.4.1 Hospital
- 2.4.2 Clinics
- 2.4.3 Others

2.5 Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application

- 2.5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Market Share by Application (2018-2023)
- 2.5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue and Market Share by Application (2018-2023)

2.5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Application (2018-2023)

3 GLOBAL IDIOPATHIC PULMONARY FIBROSIS (IPF) DRUG BY COMPANY

3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Breakdown Data by Company

3.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales by Company (2018-2023)

3.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Company (2018-2023)

3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue by Company (2018-2023)

3.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Company (2018-2023)

3.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Company (2018-2023)

3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Company

3.4 Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Product Location Distribution

3.4.2 Players Idiopathic Pulmonary Fibrosis (IPF) Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) DRUG BY GEOGRAPHIC REGION

4.1 World Historic Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Geographic Region (2018-2023)

4.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country/Region (2018-2023)

- 4.2.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth
- 4.4 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth
- 4.5 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth
- 4.6 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth

5 AMERICAS

- 5.1 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country
 - 5.1.1 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023)
 - 5.1.2 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023)
- 5.2 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
- 5.3 Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region
 - 6.1.1 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2018-2023)
 - 6.1.2 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2018-2023)
- 6.2 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type
- 6.3 APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

7.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug by Country

7.1.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023)

7.1.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023)

7.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type

7.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug by Country

8.1.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023)

8.1.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023)

8.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type

8.3 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug

10.3 Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug

10.4 Industry Chain Structure of Idiopathic Pulmonary Fibrosis (IPF) Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors

11.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Customer

12 WORLD FORECAST REVIEW FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) DRUG BY GEOGRAPHIC REGION

12.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size Forecast by Region

12.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Forecast by Region (2024-2029)

12.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Forecast by Type

12.7 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 American Lung Association

13.1.1 American Lung Association Company Information

13.1.2 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

13.1.3 American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 American Lung Association Main Business Overview

13.1.5 American Lung Association Latest Developments

13.2 Roche

13.2.1 Roche Company Information

13.2.2 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

13.2.3 Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Roche Main Business Overview

13.2.5 Roche Latest Developments

13.3 Genentech

13.3.1 Genentech Company Information

13.3.2 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

13.3.3 Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Genentech Main Business Overview

13.3.5 Genentech Latest Developments

13.4 Fierce Pharma

13.4.1 Fierce Pharma Company Information

13.4.2 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

13.4.3 Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Fierce Pharma Main Business Overview

13.4.5 Fierce Pharma Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Idiopathic Pulmonary Fibrosis (IPF) Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Nintedanib

Table 4. Major Players of Pirfenidone

Table 5. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2018-2023) & (K Units)

Table 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)

Table 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Type (2018-2023) & (\$ million)

Table 8. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type (2018-2023)

Table 9. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Type (2018-2023) & (US\$/Unit)

Table 10. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2018-2023) & (K Units)

Table 11. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2018-2023)

Table 12. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Application (2018-2023)

Table 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application (2018-2023)

Table 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Application (2018-2023) & (US\$/Unit)

Table 15. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Company (2018-2023) & (K Units)

Table 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Company (2018-2023)

Table 17. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Company (2018-2023) (\$ Millions)

Table 18. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Company (2018-2023)

Table 19. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sale Price by Company

(2018-2023) & (US\$/Unit)

Table 20. Key Manufacturers Idiopathic Pulmonary Fibrosis (IPF) Drug Producing Area Distribution and Sales Area

Table 21. Players Idiopathic Pulmonary Fibrosis (IPF) Drug Products Offered

Table 22. Idiopathic Pulmonary Fibrosis (IPF) Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Geographic Region (2018-2023) & (K Units)

Table 26. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share Geographic Region (2018-2023)

Table 27. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 28. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Geographic Region (2018-2023)

Table 29. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country/Region (2018-2023) & (K Units)

Table 30. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country/Region (2018-2023)

Table 31. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country/Region (2018-2023)

Table 33. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023) & (K Units)

Table 34. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2018-2023)

Table 35. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 36. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2018-2023)

Table 37. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2018-2023) & (K Units)

Table 38. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2018-2023) & (K Units)

Table 39. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2018-2023) & (K Units)

Table 40. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by

Region (2018-2023)

Table 41. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Region (2018-2023) & (\$ Millions)

Table 42. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Region (2018-2023)

Table 43. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2018-2023) & (K Units)

Table 44. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2018-2023) & (K Units)

Table 45. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023) & (K Units)

Table 46. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2018-2023)

Table 47. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 48. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2018-2023)

Table 49. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2018-2023) & (K Units)

Table 50. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2018-2023) & (K Units)

Table 51. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Country (2018-2023) & (K Units)

Table 52. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country (2018-2023)

Table 53. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Country (2018-2023) & (\$ Millions)

Table 54. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country (2018-2023)

Table 55. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Type (2018-2023) & (K Units)

Table 56. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Application (2018-2023) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Idiopathic Pulmonary Fibrosis (IPF) Drug

Table 58. Key Market Challenges & Risks of Idiopathic Pulmonary Fibrosis (IPF) Drug

Table 59. Key Industry Trends of Idiopathic Pulmonary Fibrosis (IPF) Drug

Table 60. Idiopathic Pulmonary Fibrosis (IPF) Drug Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Idiopathic Pulmonary Fibrosis (IPF) Drug Distributors List

Table 63. Idiopathic Pulmonary Fibrosis (IPF) Drug Customer List

Table 64. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Region (2024-2029) & (K Units)

Table 65. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 66. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Country (2024-2029) & (K Units)

Table 67. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 68. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Region (2024-2029) & (K Units)

Table 69. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Type (2024-2029) & (K Units)

Table 75. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 76. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Forecast by Application (2024-2029) & (K Units)

Table 77. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 78. American Lung Association Basic Information, Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturing Base, Sales Area and Its Competitors

Table 79. American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

Table 80. American Lung Association Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 81. American Lung Association Main Business

Table 82. American Lung Association Latest Developments

Table 83. Roche Basic Information, Idiopathic Pulmonary Fibrosis (IPF) Drug

Manufacturing Base, Sales Area and Its Competitors

Table 84. Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

Table 85. Roche Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Roche Main Business

Table 87. Roche Latest Developments

Table 88. Genentech Basic Information, Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturing Base, Sales Area and Its Competitors

Table 89. Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

Table 90. Genentech Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Genentech Main Business

Table 92. Genentech Latest Developments

Table 93. Fierce Pharma Basic Information, Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturing Base, Sales Area and Its Competitors

Table 94. Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Product Portfolios and Specifications

Table 95. Fierce Pharma Idiopathic Pulmonary Fibrosis (IPF) Drug Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. Fierce Pharma Main Business

Table 97. Fierce Pharma Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Idiopathic Pulmonary Fibrosis (IPF) Drug
- Figure 2. Idiopathic Pulmonary Fibrosis (IPF) Drug Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Idiopathic Pulmonary Fibrosis (IPF) Drug Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Nintedanib
- Figure 10. Product Picture of Pirfenidone
- Figure 11. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type in 2022
- Figure 12. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type (2018-2023)
- Figure 13. Idiopathic Pulmonary Fibrosis (IPF) Drug Consumed in Hospital
- Figure 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Hospital (2018-2023) & (K Units)
- Figure 15. Idiopathic Pulmonary Fibrosis (IPF) Drug Consumed in Clinics
- Figure 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Clinics (2018-2023) & (K Units)
- Figure 17. Idiopathic Pulmonary Fibrosis (IPF) Drug Consumed in Others
- Figure 18. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Others (2018-2023) & (K Units)
- Figure 19. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2022)
- Figure 20. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application in 2022
- Figure 21. Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market by Company in 2022 (K Units)
- Figure 22. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Company in 2022
- Figure 23. Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market by Company in

2022 (\$ Million)

Figure 24. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Company in 2022

Figure 25. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Geographic Region (2018-2023)

Figure 26. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Geographic Region in 2022

Figure 27. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales 2018-2023 (K Units)

Figure 28. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue 2018-2023 (\$ Millions)

Figure 29. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales 2018-2023 (K Units)

Figure 30. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue 2018-2023 (\$ Millions)

Figure 31. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales 2018-2023 (K Units)

Figure 32. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue 2018-2023 (\$ Millions)

Figure 33. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales 2018-2023 (K Units)

Figure 34. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue 2018-2023 (\$ Millions)

Figure 35. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country in 2022

Figure 36. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country in 2022

Figure 37. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)

Figure 38. Americas Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2018-2023)

Figure 39. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Canada Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Mexico Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Brazil Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 43. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Region in 2022

Figure 44. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Regions in 2022

Figure 45. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)

Figure 46. APAC Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2018-2023)

Figure 47. China Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 49. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 51. India Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Australia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 53. China Taiwan Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Country in 2022

Figure 55. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Country in 2022

Figure 56. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)

Figure 57. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2018-2023)

Figure 58. Germany Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 59. France Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 60. UK Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Italy Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Russia Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market

Share by Country in 2022

Figure 64. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue

Market Share by Country in 2022

Figure 65. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Type (2018-2023)

Figure 66. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share by Application (2018-2023)

Figure 67. Egypt Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 68. South Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Israel Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Turkey Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 71. GCC Country Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug in 2022

Figure 73. Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug

Figure 74. Industry Chain Structure of Idiopathic Pulmonary Fibrosis (IPF) Drug

Figure 75. Channels of Distribution

Figure 76. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Forecast by Region (2024-2029)

Figure 77. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share Forecast by Region (2024-2029)

Figure 78. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share Forecast by Type (2024-2029)

Figure 79. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share Forecast by Type (2024-2029)

Figure 80. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Market Share Forecast by Application (2024-2029)

Figure 81. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G7FC0D28E5ABEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7FC0D28E5ABEN.html>